tailieunhanh - The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway

Neo-adjuvant breast cancer clinical trials of zoledronic acid (ZOL) have shown that patients with oestrogen negative (ER-ve) tumours have improved disease outcomes. We investigated the molecular mechanism behind this differential anti-tumour effect according to ER status, hypothesising it may in part be mediated via the activin signaling pathway. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN